Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isuzinaxib in Diabetic Kidney Disease
NCT06962098Phase 2Recruiting
- Sponsor
- AptaBio Therapeutics Inc.
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of isuzinaxib in diabetic kidney disease (DKD), sponsored by AptaBio Therapeutics Inc.. Started May 2025; status: recruiting.
02
Drugs
isuzinaxib
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT06962098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962098.